The Stock that Jumped 177% in the Evening Shows: The Experiment Was Successful, the Short Failed
6 Articles
6 Articles
A successful trial of a melanoma cancer vaccine led to a huge jump in Moderna's stock, which has been struggling to find its way since the coronavirus • Investors who bet against the stock lost billions, some tried to save their money last night
Moderna and Merck not only delight patients with good results of a cancer vaccine - but also their shareholders. The Moderna share jumped by 176 percent yesterday. Also because this is about more than one vaccine.
The US plan to double public debt buybacks eases the pressure on bonds and sustains the Dow Jones and the S&P 500, while Nasdaq 100 closes in negative. Modern starring the session with an extraordinary rise after advances in melanoma are known.
Merck's shares also rebounded in the stock market 12% in New York for advances in his research. He liked an experimental vaccine.
Moderna and Merck have successfully completed the final phase of testing mRNA therapy for melanoma. Moderna's shares rose 150 percent before trading opened.
Investors who have American pharmaceutical company Moderna in their portfolios are probably not surprised. Shares of the well-known coronavirus vaccine manufacturer soared by more than 150 percent during trading on the Nasdaq stock exchange on Wednesday, but later erased some of the gains and around 6 p.m. our time...
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
